메뉴 건너뛰기




Volumn 25, Issue 4, 2014, Pages 462-471

A phase i clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections

Author keywords

Adverse events; Combretastatin A4 phosphate; Tolerated dose

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE;

EID: 84896401933     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000070     Document Type: Article
Times cited : (40)

References (14)
  • 1
    • 77956301345 scopus 로고    scopus 로고
    • Combretastatin A4 phosphate: A novel vascular disrupting agent
    • Nagaiah G, Remick SC. Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol 2010; 6: 1219-1228.
    • (2010) Future Oncol , vol.6 , pp. 1219-1228
    • Nagaiah, G.1    Remick, S.C.2
  • 2
    • 0036959614 scopus 로고    scopus 로고
    • Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors
    • Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002; 12: 1063-1070. (Pubitemid 36114813)
    • (2002) Thyroid , vol.12 , Issue.12 , pp. 1063-1070
    • Dziba, J.M.1    Marcinek, R.2    Venkataraman, G.3    Robinson, J.A.4    Ain, K.B.5
  • 3
    • 0035129337 scopus 로고    scopus 로고
    • Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: Preclinical efficacy
    • DOI 10.1097/00001813-200101000-00008
    • Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, et al. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Anticancer Drugs 2001; 12: 57-63. (Pubitemid 32142284)
    • (2001) Anti-Cancer Drugs , vol.12 , Issue.1 , pp. 57-63
    • Nabha, S.M.1    Mohammad, R.M.2    Wall, N.R.3    Dutcher, J.A.4    Salkini, B.M.5    Pettit, G.R.6    Al-Katib, A.M.7
  • 4
    • 0042887593 scopus 로고    scopus 로고
    • Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate
    • DOI 10.1200/JCO.2003.05.186
    • Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003; 21: 2823-2830. (Pubitemid 46621829)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.15 , pp. 2823-2830
    • Anderson, H.L.1    Yap, J.T.2    Miller, M.P.3    Robbins, A.4    Jones, T.5    Price, P.M.6
  • 8
    • 84862532904 scopus 로고    scopus 로고
    • Phase i trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer
    • Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res 2012; 18: 3428-3439.
    • (2012) Clin Cancer Res , vol.18 , pp. 3428-3439
    • Nathan, P.1    Zweifel, M.2    Padhani, A.R.3    Koh, D.M.4    Ng, M.5    Collins, D.J.6
  • 9
    • 77951667223 scopus 로고    scopus 로고
    • A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
    • Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS,Wang D, et al. A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010; 102: 1355-1360.
    • (2010) Br J Cancer , vol.102 , pp. 1355-1360
    • Rustin, G.J.1    Shreeves, G.2    Nathan, P.D.3    Gaya, A.4    Ganesan, T.S.5    Wang, D.6
  • 10
    • 80053970544 scopus 로고    scopus 로고
    • A report from the 47th Annual Meeting of the American Society of Clinical Oncology
    • June 3-7
    • Rabasseda X, Gomez-Zaera M. A report from the 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, Illinois, USA: Drugs of today; June 3-7, 2011; 47: 693-737.
    • (2011) Chicago Illinois USA: Drugs of Today , vol.47 , pp. 693-737
    • Rabasseda, X.1    Gomez-Zaera, M.2
  • 11
    • 79953648492 scopus 로고    scopus 로고
    • Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
    • Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011; 22: 2036-2041.
    • (2011) Ann Oncol , vol.22 , pp. 2036-2041
    • Zweifel, M.1    Jayson, G.C.2    Reed, N.S.3    Osborne, R.4    Hassan, B.5    Ledermann, J.6
  • 12
    • 12344312699 scopus 로고    scopus 로고
    • Cancer Therapy Evaluation Program., DCTD, NCI, NIH, DHHS;
    • Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, DCTD, NCI, NIH, DHHS; 2006.
    • (2006) Common Terminology Criteria for Adverse Events
  • 13
    • 79952621559 scopus 로고    scopus 로고
    • Combretastatin-induced hypertension and the consequences for its combination with other therapies
    • Busk M, Bohn AB, Skals M,Wang T, Horsman MR. Combretastatin-induced hypertension and the consequences for its combination with other therapies. Vascul Pharmacol 2011; 54: 13-17.
    • (2011) Vascul Pharmacol , vol.54 , pp. 13-17
    • Busk, M.1    Bohn, A.B.2    Skals, M.3    Wang, T.4    Horsman, M.R.5
  • 14
    • 79955804161 scopus 로고    scopus 로고
    • A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours
    • He X, Li S, Huang H, Li Z, Chen L, Ye S, et al. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. Br J Clin Pharmacol 2011; 71: 860-870.
    • (2011) Br J Clin Pharmacol , vol.71 , pp. 860-870
    • He, X.1    Li, S.2    Huang, H.3    Li, Z.4    Chen, L.5    Ye, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.